Management of Uterine Fibroids and Leiomyomas

Uterine fibroids and leiomyomas are benign smooth muscle tumours affecting a substantial proportion of women of reproductive age worldwide. Clinical manifestations vary from asymptomatic cases to heavy menstrual bleeding, pelvic pain and pressure symptoms that impair quality of life. Management strategies span conservative monitoring, pharmacological interventions, image‐guided procedures and surgery. Pharmacological options include gonadotrophin‐releasing hormone analogues, selective progesterone receptor modulators and aromatase inhibitors, which aim to reduce bleeding and tumour volume. Minimally invasive techniques such as uterine artery embolisation and high‐intensity focused ultrasound offer uterine‐preserving alternatives with shorter recovery times. Myomectomy remains the standard for women desiring future fertility, whereas hysterectomy provides definitive treatment. A growing emphasis on personalised care integrates symptom severity, fertility desires and molecular characteristics of individual tumours to guide intervention choice and optimise long‐term outcomes.

Research from Nature Portfolio

Recent studies have engineered precise MED12 hotspot mutations in smooth muscle cells to establish a three‐dimensional cellular model that faithfully reproduces fibroid characteristics, including altered metabolic pathways, enhanced proliferation and extensive extracellular matrix deposition. This platform enables functional dissection of mutation‐driven gene networks and preclinical screening of targeted therapies. Complementary genetic research has applied large‐scale genome‐wide association and epidemiological analyses to identify novel susceptibility loci for uterine leiomyomata and overlapping risk variants with endometriosis. These findings elucidate shared pathogenic mechanisms, suggest biomarkers for risk stratification and open avenues for genotype‐guided management strategies.

Management of Uterine Fibroids and Leiomyomas publication trend

The graph below shows the total number of articles in management of uterine fibroids and leiomyomas across all publications each year (not limited to Nature Index journals).

Technical terms

MED12 mutation: A change in the gene encoding mediator complex subunit 12, commonly found in fibroid cells and driving tumour growth.

Extracellular matrix: The network of collagen and glycoproteins surrounding cells; excessive deposition contributes to fibroid rigidity and enlargement.

Uterine artery embolisation: A minimally invasive procedure that occludes fibroid blood supply to induce shrinkage and symptom relief.

High‐intensity focused ultrasound (HIFU): A non‐invasive technique using focused sound waves to thermally ablate fibroid tissue under imaging guidance.

Gonadotrophin‐releasing hormone analogue: A medication that down‐regulates pituitary stimulation of ovarian hormones, reducing fibroid size and menstrual bleeding.

References

1. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women's Health (2012).
2. Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization. Nature Communications (2023).
3. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. Nature Communications (2019).
4. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Molecular Medicine (2015).
5. Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases. International Journal of Hyperthermia (2018).
6. Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. Journal of Obstetrics and Gynaecology Research (2017).